Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift

Fineline Cube Feb 2, 2026
Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Chiesi Fabry Drug Pegunigalsidase Alfa Wins CHMP Backing for Extended Dosing

Fineline Cube Feb 2, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Beijing Aosaikang’s Combo Therapy for NSCLC Accepted for Clinical Trial by NMPA

Fineline Cube Nov 13, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...

Company

Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters

Fineline Cube Nov 13, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the...

Company

Sandoz Invests in New Biosimilars and Penicillin API Production Sites in Europe

Fineline Cube Nov 13, 2023

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced the opening of two new production sites...

Company

Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments

Fineline Cube Nov 10, 2023

Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023,...

Company Deals

AimingMed Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine

Fineline Cube Nov 10, 2023

AimingMed, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a...

Company Drug

China’s NMPA Grants Conditional Approval for Juventas’ CAR-T Therapy Inaticabtagene Autoleucel

Fineline Cube Nov 10, 2023

The National Medical Products Administration (NMPA) has conditionally approved the marketing of inaticabtagene autoleucel (CNCT...

Policy / Regulatory

China’s NMPA Officially Seeks Membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S)

Fineline Cube Nov 10, 2023

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults

Fineline Cube Nov 10, 2023

Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...

Company

BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase

Fineline Cube Nov 10, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...

Company Deals Hospital

Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties

Fineline Cube Nov 10, 2023

US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore HSA Nod for Phase I Study of 177Lu-LNC1003

Fineline Cube Nov 10, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases

Fineline Cube Nov 10, 2023

Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm...

Company Drug

Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China

Fineline Cube Nov 10, 2023

China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of...

Company Deals

Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing

Fineline Cube Nov 10, 2023

China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon...

Company Medical Device

Sino Medical Sciences Technology Secures EU MDR Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Nov 10, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received Medical...

Company Deals

Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements

Fineline Cube Nov 10, 2023

Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with...

Company Deals

Bayer Secures Multiple Procurement Deals at the 6th CIIE

Fineline Cube Nov 10, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced...

Company Deals

ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions

Fineline Cube Nov 10, 2023

Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co.,...

Company Drug

Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia

Fineline Cube Nov 10, 2023

Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in...

Company Drug

ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study

Fineline Cube Nov 10, 2023

Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in...

Posts pagination

1 … 396 397 398 … 617

Recent updates

  • Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift
  • Chiesi Fabry Drug Pegunigalsidase Alfa Wins CHMP Backing for Extended Dosing
  • Novo Nordisk Appoints Yan Cai as Greater China President Amid LeadershipChange
  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift

Company Drug

Chiesi Fabry Drug Pegunigalsidase Alfa Wins CHMP Backing for Extended Dosing

Company

Novo Nordisk Appoints Yan Cai as Greater China President Amid LeadershipChange

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.